Evidence map›Paper›PMID 15544030›Full record

ReviewMolecular and cellular biochemistry2004

Growth factor activation in myocardial vascularization: therapeutic implications.

Robert J Tomanek, Wei Zheng, Xinping Yue

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Bioengineering the infarcted heart by applying bio-inspired materials.Journal of cardiovascular translational research · 2011
    Article
  4. Combining neuropeptide Y and mesenchymal stem cells reverses remodeling after myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2010
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robert J TomanekDepartment of Anatomy and Cell Biology, University of Iowa, Iowa City, IA 52242, USA. robert-tomanek@uiowa.edu
Wei Zheng
Xinping Yue
University of Iowa · US

Funding

SPATIAL /TEMPORAL REGULATION OF CORONARY VASCULOGENESIS/ANGIOGENESISP50HL062178 · NHLBI · UNIVERSITY OF IOWA · PI LAUER, RONALD M · 1999 to 2003
$3.8M
ANGIOGENIC THERAPY FOR INFARCTED AND ISCHEMIC HEARTR01HL062587 · NHLBI · UNIVERSITY OF IOWA · PI TOMANEK, ROBERT J · 2000 to 2003
$1.3M
NHLBI NIH HHS HL62178NHLBI NIH HHS HL62587
6 · The paper itself

Abstract

A rapid growth of the coronary vasculature occurs during prenatal and early postnatal periods as precursor cells from the epi- and sub-epicardium differentiate, migrate and form vascular structures (vasculogenesis) which then fuse, branch and in some cases recruit cells to form three tunics (angiogenesis). These processes are tightly controlled by temporally and spatially expressed growth factors which are stimulated by metabolic and mechanical factors. The process of angiogenesis in the myocardium is not limited to developmental periods of life, but may occur when the heart is challenged by enhanced loading conditions or during hypoxia or ischemia. This review focuses on the activation of growth factors by metabolic and mechanical stimuli in the developing heart and in the adult heart undergoing adaptive responses. Experimental studies support the hypotheses that both metabolic (hypoxia) and mechanical (stretch) factors serve as powerful stimuli for the up-regulation of growth factors which facilitate angiogenesis and arteriogenesis. Both hypoxia and stretch are powerful inducers of VEGF and its receptors, and provide for paracrine and autocrine signaling. In addition to the VEGF family, bFGF and angiopoietins play major roles in myocardial vascularization. Sufficient evidence supports the hypothesis that mechanical (e.g., bradycardia) and metabolic (e.g., thyroxine analogs) may provide effective non-invasive angiogenic therapies for the ischemic and post-infarcted heart.

Indexed as

Gene Expression Regulation, DevelopmentalAnimalsCoronary VesselsFibroblast Growth Factor 2Growth SubstancesHeartHumansHypoxiaModels, BiologicalNeovascularization, PathologicNeovascularization, PhysiologicSignal TransductionUp-RegulationVascular Endothelial Growth Factor AFibroblast Growth Factor 2Growth SubstancesVascular Endothelial Growth Factor A

Identifiers

PMID15544030
OpenAlexW2045630406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.